AR025902A1 - RECEIVER AGONISTS 3 (R3) OF THE PITUITARY CYCLING ADENYLATE ACTIVATING PEPTIDE AND ITS PHARMACOLOGICAL USE METHODS - Google Patents
RECEIVER AGONISTS 3 (R3) OF THE PITUITARY CYCLING ADENYLATE ACTIVATING PEPTIDE AND ITS PHARMACOLOGICAL USE METHODSInfo
- Publication number
- AR025902A1 AR025902A1 ARP000105130A AR025902A1 AR 025902 A1 AR025902 A1 AR 025902A1 AR P000105130 A ARP000105130 A AR P000105130A AR 025902 A1 AR025902 A1 AR 025902A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptides
- pituitary
- cycling
- insulin
- use methods
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 3
- 230000003213 activating effect Effects 0.000 title 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 230000001351 cycling effect Effects 0.000 title 1
- 230000000144 pharmacologic effect Effects 0.000 title 1
- 230000001817 pituitary effect Effects 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 7
- 230000003914 insulin secretion Effects 0.000 abstract 3
- 229940122199 Insulin secretagogue Drugs 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 abstract 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 abstract 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 abstract 1
- 241000700159 Rattus Species 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 208000016097 disease of metabolism Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 210000004153 islets of langerhan Anatomy 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta presenta novedosos péptidos que funcionan in vivo para estimular la liberacion de insulina de las células beta pancreáticas en forma dependiente de laglucosa. Se ha demostrado que estos péptidos secretagogos de insulina estimulan la liberacion de insulina en las células de islotes de ratas in vitro e invivo. Los péptidos de la presente proporcionan una nueva terapia para pacientes con secrecion de insulina disminuida, en especial diabéticos de tipo 2. Enespecial, la presente es un polipéptido seleccionado entre un grupo específico de polipéptidos relacionados con VIP/PACAP, o equivalentes funcionales delmismo. La presente se refiere asimismo a un método para tratar una enfermedad metabolica en un mamífero que comprende administrar unacantidad terapéuticamenteefectiva de los péptidos secretagogos de insulina a dicho mamífero. También se describen métodos para preparar los péptidos, tanto recombinantes comosintéticos.This presents novel peptides that work in vivo to stimulate insulin release from pancreatic beta cells in a laglucose-dependent manner. These insulin secretagogue peptides have been shown to stimulate insulin release in islet cells of rats in vitro and invivo. The peptides herein provide a new therapy for patients with decreased insulin secretion, especially type 2 diabetics. In particular, this is a polypeptide selected from a specific group of VIP / PACAP-related polypeptides, or functional equivalents thereof. This also refers to a method for treating a metabolic disease in a mammal that comprises administering a therapeutically effective amount of insulin secretagogue peptides to said mammal. Methods are also described for preparing peptides, both comosynthetic recombinants.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40783299A | 1999-09-28 | 1999-09-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR025902A1 true AR025902A1 (en) | 2002-12-18 |
Family
ID=45570861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000105130 AR025902A1 (en) | 1999-09-28 | 2000-09-28 | RECEIVER AGONISTS 3 (R3) OF THE PITUITARY CYCLING ADENYLATE ACTIVATING PEPTIDE AND ITS PHARMACOLOGICAL USE METHODS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR025902A1 (en) |
-
2000
- 2000-09-28 AR ARP000105130 patent/AR025902A1/en not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2000000071A (en) | RECEIVER AGONISTS 3 (R3) OF THE PITUITARY CYCLING ADENYLATE ACTIVATING PEPTIDE AND ITS PHARMACOLOGICAL USE METHODS | |
| UY27893A1 (en) | AGONISTS OF THE RECEIVER (VPAC2) OF THE ACTIVATING PEPTIDE OF THE HYPOFISARY ADENYLATOCICLASS (PACAP) AND ITS PHARMACOLOGICAL USE METHODS | |
| Smallridge | Thyrotropin-secreting pituitary tumors | |
| Crawley et al. | Activity of centrally administered galanin fragments on stimulation of feeding behavior and on galanin receptor binding in the rat hypothalamus | |
| JP3262329B2 (en) | GLP-1 analog useful for the treatment of diabetes | |
| EP0438519B1 (en) | Therapeutic peptides | |
| RU2001136014A (en) | RECEPTOR-3 (R3) AGONISTS OF THE PEPTIDE ACTIVATOR OF THE PITUITARY ADENYLATICLICASE (RASAR) AND METHODS OF THEIR PHARMACOLOGICAL APPLICATION | |
| JP2005501058A (en) | GLP-1, EXENDIN-4, peptide analogue thereof and use thereof | |
| US20130195807A1 (en) | Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets | |
| CN104144704B (en) | The receptor agonist peptides gastrin conjugates of GLP 1 | |
| DK0699686T3 (en) | Biologically active fragments of glucagon-like insulinotropic peptide | |
| US20130261058A1 (en) | Acceleration of wound healing by growth hormone releasing hormone and its agonists | |
| ATE139540T1 (en) | MEDICINAL PEPTIDES | |
| WO1992009626A1 (en) | Nonapeptide bombesin antagonists | |
| Nakagami et al. | Effects of serotonin, cyproheptadine and reserpine on corticotropin-releasing factor release from the rat hypothalamus in vitro | |
| TW200530270A (en) | Pharmaceutical composition for treating tumors comprising growth hormone releasing compounds or their antagonists | |
| WO1995021194A1 (en) | Superactive vip antagonists | |
| AR025902A1 (en) | RECEIVER AGONISTS 3 (R3) OF THE PITUITARY CYCLING ADENYLATE ACTIVATING PEPTIDE AND ITS PHARMACOLOGICAL USE METHODS | |
| O'Byrne et al. | Somatostatin and the lung | |
| ECSP003683A (en) | RECEIVER AGONISTS 3 (R3) OF THE PITUITARY CYCLING ADENYLATE ACTIVATING PEPTIDE AND ITS PHARMACOLOGICAL USE METHODS | |
| BRPI0507177A (en) | (vpac2) agonists of the pituitary adenylate cyclase activation peptide receptor (pacap) and their pharmacological methods of use | |
| Markoff et al. | Effects of prolactin and glycosylated prolactin on (pro) insulin synthesis and insulin release from cultured rat pancreatic islets | |
| Wada et al. | Effect of a new bombesin receptor antagonist,(E)-alkene bombesin isostere, on amylase release from rat pancreatic acini | |
| Taminato et al. | Bombesin inhibits insulin release from isolated pancreatic islets of rats in vitro | |
| Gargosky et al. | C-terminal bombesin sequence requirements for binding and effects on protein synthesis in Swiss 3T3 cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |